Selective EGF-Receptor Inhibition in CD4 + T Cells Induces Anergy and Limits Atherosclerosis

Several epidermal growth factor receptor (EGFR) inhibitors have been successfully developed for the treatment of cancer, limiting tumor growth and metastasis. EGFR is also expressed by leukocytes, but little is known about its role in the modulation of the immune response. The aim of this study was...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 71; no. 2; p. 160
Main Authors:	Zeboudj, Lynda, Maître, Mikael, Guyonnet, Lea, Laurans, Ludivine, Joffre, Jeremie, Lemarie, Jeremie, Bourcier, Simon, Nour-Eldine, Wared, Guérin, Coralie, Friard, Jonas, Wakkach, Abdelilah, Fabre, Elizabeth, Tedgui, Alain, Mallat, Ziad, Tharaux, Pierre-Louis, Ait-Oufella, Hafid
Format:	Journal Article
Language:	English
Published:	United States 16.01.2018
Subjects:	Animals Antineoplastic Agents - pharmacology Atherosclerosis - immunology CD4-Positive T-Lymphocytes - immunology Cytokines - analysis Cytokines - classification Cytokines - immunology ErbB Receptors - antagonists & inhibitors Erlotinib Hydrochloride - pharmacology Immunity, Cellular - drug effects Immunity, Cellular - immunology Mice Plaque, Atherosclerotic - drug therapy Plaque, Atherosclerotic - immunology Plaque, Atherosclerotic - pathology Protein Kinase Inhibitors - pharmacology T-Lymphocytes, Regulatory - immunology atherosclerosis immunity inflammation lymphocyte
ISSN:	1558-3597, 1558-3597
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!